IPO take 2: Kindler's Centrexion restarts bid to fund pain trial

Centrexion Therapeutics has restarted its attempt to list on the Nasdaq. The Jeff Kindler-helmed biotech pulled the plug on a planned IPO last year but now hopes to find investors more amenable to its bid to raise money for a phase 3 pain program.